Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Figures corrected NBB
Corrected annual account filed for 2022.
-
Busy address KBO
14 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
AstraZeneca from Dilbeek, company number BE0400165679, closed financial year 2025 with a result of € 8.6 million after tax. For that financial year AstraZeneca recorded revenue of € 351.2 million and equity of € 46.9 million. Compared with financial year 2024, the result moved from € 8.2 million to € 8.6 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 17, 2026.
€ 46.9 million
▲ 23% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 8.6 million
▲ 6% vs 2024
Profit after tax over the fiscal year.
€ 1.5 million
▲ 96% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 20.3 million.
People and assets in 2025
234.4
▲ 12.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 43.7 million
▲ 10% vs 2024
€ 186,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 63,865
▲ 39% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 47.4 million
▲ 23% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 98 days on average.
€ 11.1 million
▼ 2% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 226,128,219 | € 278,669,075 | € 317,480,461 | € 351,224,744 | ▲ 11% |
| Profit after taxes | € 5,206,757 | € 9,109,409 | € 8,191,283 | € 8,647,168 | ▲ 6% |
| Equity | € 53,932,686 | € 63,042,095 | € 38,233,378 | € 46,880,546 | ▲ 23% |
| Total debts | € 45,659,686 | € 31,078,451 | € 49,812,460 | € 58,500,385 | ▲ 17% |
| Cash | € 1,258,923 | € 1,020,203 | € 752,524 | € 1,475,916 | ▲ 96% |
| Retained profit | € 27,348,961 | € 36,458,370 | € 11,649,652 | € 20,296,820 | ▲ 74% |
| Dividend | € 0 | € 0 | € 33,000,000 | € 0 | ▼ 100% |
| Bank debt | € 323,886 | € 0 | € 0 | € 0 | |
| Balance sheet total | € 99,592,372 | € 94,120,546 | € 88,045,837 | € 105,380,930 | ▲ 20% |
| Employees (FTE) | 187.2 | 211.5 | 221.7 | 234.4 | ▲ 12.7 |
Key figures of AstraZeneca, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to AstraZeneca?
What happened at AstraZeneca in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Luca Taliercio stepped down as director. NBB
- Paul Van Mullem stepped down as director. NBB
- Jennifer Olivero stepped down as director. NBB
- Angela Thompson stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 8.6 million (▲ 6% vs 2024). Source: NBB ↗
- New establishment in Mont-Saint-Guibert. KBO
- New establishment in Mont-Saint-Guibert. KBO
- Angela Thompson became a director. NBB
In short
From € 5.2 million profit in 2022 to € 8.6 million profit in 2025.
Paid € 11.9 million in corporate taxes since 2022.
Best year ever: 2023, with € 9.1 million profit.
Paid out € 33 million in dividends to the owners in total.
Management
The shares are held by AstraZeneca Continent BV and AstraZeneca Gamma BV.
Directors
According to the 2025 annual accounts
Luca Taliercio
Director
since 2022 · until 2028
Paul Van Mullem
Director
since 2022 · until 2028
Jennifer Olivero
Director
since 2022 · until 2028
Angela Thompson
Managing director
since 2025 · until 2028
Shareholders
AstraZeneca Continent BV
AstraZeneca Gamma BV
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Alfons Gossetlaan 40 box 201
1702 Dilbeek
Rue André Dumont 5
1435 Mont-Saint-Guibert
Active since 1 October 2025
Rue André Dumont 9
1435 Mont-Saint-Guibert
Active since 1 October 2025
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 14 companies are registered at this address.
All companies at this address →Intersong-Primavera, Editions Musicales
€ 42,007 revenue · 2024
Babel Music
€ 3,662 revenue · 2024
WARNER MUSIC BENELUX
€ 4.5 million gross margin · 2025
Amplifon Belgium
€ 47.6 million revenue · 2025
WARNER CHAPPELL MUSIC BELGIUM
€ 4 million revenue · 2024
+9 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0400.165.679
- VAT number
- BE 0400.165.679
- Registered office
- Alfons Gossetlaan 40 bus 201, 1702 Dilbeek
- Names & denominations
- AstraZeneca
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 28 November 1948
- Peppol
- Active · Active since 30 Dec 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten